Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.52 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6248799 | 0.81 | HPGD (0.45) | HPGDNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL13884337 | 0.81 | LMNA (0.48) | ESR1HPGDLMNAESR2HTT | |
| SCHEMBL16240889 | 0.81 | ESR1 (0.56) | ESR1THRATHRBHPGDNPC1 | |
| SCHEMBL14670707 | 0.80 | ESR1 (0.50) | ESR1THRATHRBHPGDNPC1 | |
| SCHEMBL6685103 | 0.80 | ESR1 (0.74) | ESR1THRATHRBLMNASLC6A2 | |
| SCHEMBL4603900 | 0.80 | IDO1 (0.39) | THRBHPGDNPC1RAB9ALMNA | |
| SCHEMBL21298845 | 0.79 | ESR1 (0.41) | ESR1THRATHRBHPGDNPC1 | |
| SCHEMBL13233319 | 0.79 | ESR1 (0.54) | ESR1THRATHRBHPGDLMNA | |
| SCHEMBL19295451 | 0.78 | NPC1 (0.40) | HPGDNPC1RAB9ASLC6A2 | |
| SCHEMBL18812301 | 0.78 | ESR1 (0.44) | ESR1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12019371-B2 | Photosensitive composition, film, color filter, solid-state imaging element, and image display device | FUJIFILM CORPORATION (JP) | 2024-06-25 | — | — | US | disclosed |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| EP-3407916-B1 | PHOSPHONATE LINKERS AND THEIR USE TO FACILITATE CELLULAR RETENTION OF COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | NOVARTIS AG (CH) | 2023-10-10 | — | — | US | disclosed |
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | NOVARTIS AG (CH) | 2023-10-10 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11730817-B2 | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction | INVIVOGEN (FR) | 2023-08-22 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20140065075-A1 | TARGETED CONTRAST AGENTS AND USES THEREOF | RF THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | US | disclosed |
| US-8562953-B2 | Dendritic polymers and magnetic resonance imaging contrast agent employing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2013-10-22 | — | — | US | disclosed |
| US-20130030139-A1 | DENDRITIC POLYMERS AND MAGNETIC RESONANCE IMAGING CONTRAST AGENT EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2013-01-31 | — | — | US | disclosed |
| US-8303937-B2 | Dendritic polymers and magnetic resonance imaging contrast agent employing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2012-11-06 | — | — | US | disclosed |
| US-20090169480-A1 | DENDRITIC POLYMERS AND MAGNETIC RESONANCE IMAGING CONTRAST AGENT EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2009-07-02 | — | — | US | disclosed |
| US-20090169481-A1 | DENDRITIC POLYMERS AND MAGNETIC RESONANCE IMAGING CONTRAST AGENT EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | GNA15, GNA11, EEA1 | ESR1 3287/4885THRA 3239/4885THRB 3721/4885 |
| US-20090169481-A1 | DENDRITIC POLYMERS AND MAGNETIC RESONANCE IMAGING CONTRAST AGENT EMPLOYING THE SAME | DCLK1, MSR1, S1PR3 | ESR1 3624/4885THRA 4502/4885THRB 4650/4885 |
| US-11730817-B2 | Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction | STING1, CGAS, TLR9 | ESR1 3545/4885THRA 3687/4885THRB 3397/4885 |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | ESR1 4726/4885THRA 3163/4885THRB 2762/4885 |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | ESR1 3967/4885THRA 3963/4885THRB 3616/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | ESR1 1132/4885THRA 2185/4885THRB 2605/4885 |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | AURKC, AURKA, AURKB | ESR1 2968/4885THRA 3267/4885THRB 3102/4885 |
| US-20140065075-A1 | TARGETED CONTRAST AGENTS AND USES THEREOF | ANTXR2, CALCOCO2, PAICS | ESR1 4117/4885THRA 2600/4885THRB 3564/4885 |
| US-20090169480-A1 | DENDRITIC POLYMERS AND MAGNETIC RESONANCE IMAGING CONTRAST AGENT EMPLOYING THE SAME | CD14, DCUN1D3, CCR3 | ESR1 3929/4885THRA 3177/4885THRB 4028/4885 |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | TPX2, H1-4, MAPT | ESR1 1807/4885THRA 531/4885THRB 251/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | ESR1 1237/4885THRA 952/4885THRB 703/4885 |
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | CTSB, CTSE, CTSZ | ESR1 2105/4885THRA 2773/4885THRB 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.